Next Gen Pharma India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.14 M
- Company Age 20 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.17 M
- Revenue Growth -30.03%
- Profit Growth -2.56%
- Ebitda 306.77%
- Net Worth 8.52%
- Total Assets 25.49%
About Next Gen Pharma India
Next Gen Pharma India Private Limited (NGPIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 31 December 2004 and has a history of 20 years and one month. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.14 M.
The company currently has active open charges totaling ₹2.17 M.
Kanwaldeep Chadha, Sandeep Juneja, Anuja Chadha, and One other member serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909DL2004PTC131754
-
Company No.
131754
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
31 Dec 2004
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Next Gen Pharma India?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kanwaldeep Chadha
|
Director | 31-Dec-2004 | Current |
|
Anuja Chadha
|
Director | 17-Jun-2021 | Current |
|
Jeetendra Jain
|
Director | 04-Apr-2024 | Current |
|
Sandeep Juneja
|
Director | 04-Apr-2024 | Current |
Financial Performance of Next Gen Pharma India.
Next Gen Pharma India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 30.03% decrease. The company also saw a slight decrease in profitability, with a 2.56% decrease in profit. The company's net worth moved up by a moderate rise of 8.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Next Gen Pharma India?
In 2022, Next Gen Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Aanvee Healthsciences LlpKanwaldeep Chadha and Anuja Chadha are mutual person
-
Emergere Animal Health Consulting Llp
Sandeep Juneja is a mutual person
-
Bionex Vetcare Private Limited
Sandeep Juneja is a mutual person
-
Fintegrity Consulting Llp
Jeetendra Jain is a mutual person
-
Shri Parshwa Advisors (Opc) Private Limited
Jeetendra Jain is a mutual person
-
Mortechy Finserv Private Limited
Jeetendra Jain is a mutual person
Charges (Loans)
₹2.17 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.22 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Mar 2023 | Hdfc Bank Limited | ₹2.17 M | Open |
How Many Employees Work at Next Gen Pharma India?
Unlock and access historical data on people associated with Next Gen Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Next Gen Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Next Gen Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
